Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study

DOI record: { "DOI": "10.1016/s1473-3099(22)00507-2", "ISSN": [ "1473-3099" ], "URL": "http://dx.doi.org/10.1016/S1473-3099(22)00507-2", "alternative-id": [ "S1473309922005072" ], "assertion": [ { "label": "This article is maintained by", "name": "publisher", "value": "Elsevier" }, { "label": "Article Title", "name": "articletitle", "value": "Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study" }, { "label": "Journal Title", "name": "journaltitle", "value": "The Lancet Infectious Diseases" }, { "label": "CrossRef DOI link to publisher maintained version", "name": "articlelink", "value": "https://doi.org/10.1016/S1473-3099(22)00507-2" }, { "label": "CrossRef DOI link to the associated document", "name": "associatedlink", "value": "https://doi.org/10.1016/S1473-3099(22)00522-9" }, { "label": "Content Type", "name": "content_type", "value": "article" }, { "label": "Copyright", "name": "copyright", "value": "© 2022 Elsevier Ltd. All rights reserved." } ], "author": [ { "affiliation": [], "family": "Wong", "given": "Carlos K H", "sequence": "first" }, { "affiliation": [], "family": "Au", "given": "Ivan C H", "sequence": "additional" }, { "affiliation": [], "family": "Lau", "given": "Kristy T K", "sequence": "additional" }, { "affiliation": [], "family": "Lau", "given": "Eric H Y", "sequence": "additional" }, { "affiliation": [], "family": "Cowling", "given": "Benjamin J", "sequence": "additional" }, { "affiliation": [], "family": "Leung", "given": "Gabriel M", "sequence": "additional" } ], "container-title": "The Lancet Infectious Diseases", "container-title-short": "The Lancet Infectious Diseases", "content-domain": { "crossmark-restriction": true, "domain": [ "clinicalkey.fr", "clinicalkey.jp", "clinicalkey.es", "clinicalkey.com.au", "clinicalkey.com", "em-consulte.com", "thelancet.com", "elsevier.com", "sciencedirect.com" ] }, "created": { "date-parts": [ [ 2022, 8, 24 ] ], "date-time": "2022-08-24T22:34:53Z", "timestamp": 1661380493000 }, "deposited": { "date-parts": [ [ 2022, 8, 24 ] ], "date-time": "2022-08-24T22:35:19Z", "timestamp": 1661380519000 }, "indexed": { "date-parts": [ [ 2022, 8, 24 ] ], "date-time": "2022-08-24T23:12:45Z", "timestamp": 1661382765673 }, "is-referenced-by-count": 1, "issued": { "date-parts": [ [ 2022, 8 ] ] }, "language": "en", "license": [ { "URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 8, 1 ] ], "date-time": "2022-08-01T00:00:00Z", "timestamp": 1659312000000 } } ], "link": [ { "URL": "https://api.elsevier.com/content/article/PII:S1473309922005072?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://api.elsevier.com/content/article/PII:S1473309922005072?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining" } ], "member": "78", "original-title": [], "prefix": "10.1016", "published": { "date-parts": [ [ 2022, 8 ] ] }, "published-print": { "date-parts": [ [ 2022, 8 ] ] }, "publisher": "Elsevier BV", "reference": [ { "DOI": "10.3389/fphar.2022.816429", "article-title": "Effectiveness of antiviral therapy in highly-transmissible variants of SARS-CoV-2: a modeling and simulation study", "author": "Schöning", "doi-asserted-by": "crossref", "journal-title": "Front Pharmacol", "key": "10.1016/S1473-3099(22)00507-2_bib5", "volume": "13", "year": "2022" }, { "DOI": "10.1016/j.dsx.2022.102396", "article-title": "An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19", "author": "Singh", "doi-asserted-by": "crossref", "journal-title": "Diabetes Metab Syndr", "key": "10.1016/S1473-3099(22)00507-2_bib6", "volume": "16", "year": "2022" }, { "DOI": "10.3389/fimmu.2022.855496", "article-title": "Molnupiravir and its antiviral activity against COVID-19", "author": "Tian", "doi-asserted-by": "crossref", "journal-title": "Front Immunol", "key": "10.1016/S1473-3099(22)00507-2_bib7", "volume": "13", "year": "2022" }, { "DOI": "10.1136/bmj.o443", "article-title": "Molnupiravir's authorisation was premature", "author": "Brophy", "doi-asserted-by": "crossref", "first-page": "o443", "journal-title": "BMJ", "key": "10.1016/S1473-3099(22)00507-2_bib8", "volume": "376", "year": "2022" }, { "article-title": "COVID-19: FDA expert panel recommends authorising molnupiravir but also voices concerns", "author": "Dyer", "journal-title": "BMJ", "key": "10.1016/S1473-3099(22)00507-2_bib9", "volume": "375", "year": "2021" }, { "DOI": "10.1136/bmj.o977", "article-title": "Imbalance in baseline characteristics in molnupiravir trials", "author": "Hama", "doi-asserted-by": "crossref", "first-page": "o977", "journal-title": "BMJ", "key": "10.1016/S1473-3099(22)00507-2_bib10", "volume": "377", "year": "2022" }, { "DOI": "10.1016/S1473-3099(22)00119-0", "article-title": "Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach", "author": "Dal-Ré", "doi-asserted-by": "crossref", "first-page": "e231", "journal-title": "Lancet Infect Dis", "key": "10.1016/S1473-3099(22)00507-2_bib11", "volume": "22", "year": "2022" }, { "DOI": "10.1016/j.eclinm.2021.100743", "article-title": "Clinical outcomes of different therapeutic options for COVID-19 in two Chinese case cohorts: a propensity-score analysis", "author": "Wong", "doi-asserted-by": "crossref", "journal-title": "EClinicalMedicine", "key": "10.1016/S1473-3099(22)00507-2_bib12", "volume": "32", "year": "2021" }, { "DOI": "10.1016/S1473-3099(22)00345-0", "article-title": "Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study", "author": "McMenamin", "doi-asserted-by": "crossref", "journal-title": "Lancet Infect Dis", "key": "10.1016/S1473-3099(22)00507-2_bib13", "year": "2022" }, { "DOI": "10.1001/jamainternmed.2020.6252", "article-title": "Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19", "author": "Gupta", "doi-asserted-by": "crossref", "first-page": "41", "journal-title": "JAMA Intern Med", "key": "10.1016/S1473-3099(22)00507-2_bib17", "volume": "181", "year": "2021" }, { "DOI": "10.1186/s13054-020-03422-3", "article-title": "Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study", "author": "Monedero", "doi-asserted-by": "crossref", "first-page": "2", "journal-title": "Crit Care", "key": "10.1016/S1473-3099(22)00507-2_bib18", "volume": "25", "year": "2021" }, { "DOI": "10.1093/aje/kwab028", "article-title": "Biases in evaluating the safety and effectiveness of drugs for the treatment of COVID-19: designing real-world evidence studies", "author": "Renoux", "doi-asserted-by": "crossref", "first-page": "1452", "journal-title": "Am J Epidemiol", "key": "10.1016/S1473-3099(22)00507-2_bib19", "volume": "190", "year": "2021" }, { "DOI": "10.1093/cid/ciab631", "article-title": "Clinical improvement, outcomes, antiviral activity, and costs associated with early treatment with remdesivir for patients with coronavirus disease 2019 (COVID-19)", "author": "Wong", "doi-asserted-by": "crossref", "first-page": "1450", "journal-title": "Clin Infect Dis", "key": "10.1016/S1473-3099(22)00507-2_bib20", "volume": "74", "year": "2022" }, { "DOI": "10.1002/sim.4067", "article-title": "Multiple imputation using chained equations: issues and guidance for practice", "author": "White", "doi-asserted-by": "crossref", "first-page": "377", "journal-title": "Stat Med", "key": "10.1016/S1473-3099(22)00507-2_bib22", "volume": "30", "year": "2011" }, { "DOI": "10.1177/0962280217713032", "article-title": "Propensity score analysis with partially observed covariates: how should multiple imputation be used?", "author": "Leyrat", "doi-asserted-by": "crossref", "first-page": "3", "journal-title": "Stat Methods Med Res", "key": "10.1016/S1473-3099(22)00507-2_bib23", "volume": "28", "year": "2019" }, { "DOI": "10.1002/bimj.200810488", "article-title": "Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations", "author": "Austin", "doi-asserted-by": "crossref", "first-page": "171", "journal-title": "Biom J", "key": "10.1016/S1473-3099(22)00507-2_bib24", "volume": "51", "year": "2009" }, { "DOI": "10.1093/cid/ciac180", "article-title": "Molnupiravir and nirmatrelvir–ritonavir: oral COVID antiviral drugs", "author": "Saravolatz", "doi-asserted-by": "crossref", "journal-title": "Clin Infect Dis", "key": "10.1016/S1473-3099(22)00507-2_bib25", "year": "2022" }, { "DOI": "10.1056/NEJMoa2118542", "article-title": "Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19", "author": "Hammond", "doi-asserted-by": "crossref", "first-page": "1397", "journal-title": "N Engl J Med", "key": "10.1016/S1473-3099(22)00507-2_bib27", "volume": "386", "year": "2022" }, { "DOI": "10.1056/NEJMoa2116044", "article-title": "Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients", "author": "Jayk Bernal", "doi-asserted-by": "crossref", "first-page": "509", "journal-title": "N Engl J Med", "key": "10.1016/S1473-3099(22)00507-2_bib28", "volume": "386", "year": "2022" }, { "article-title": "Effectiveness of paxlovid in reducing severe COVID-19 and mortality in high risk patients", "author": "Najjar-Debbiny", "journal-title": "Clin Infect Dis", "key": "10.1016/S1473-3099(22)00507-2_bib29", "year": "2022" }, { "article-title": "Oral nirmatrelvir and severe COVID-19 outcomes during the omicron surge", "author": "Arbel", "journal-title": "Research Square", "key": "10.1016/S1473-3099(22)00507-2_bib30", "year": "2022" }, { "DOI": "10.1056/EVIDoa2100044", "article-title": "Randomized trial of molnupiravir or placebo in patients hospitalized with COVID-19", "author": "Arribas", "doi-asserted-by": "crossref", "journal-title": "NEJM Evidence", "key": "10.1016/S1473-3099(22)00507-2_bib31", "volume": "1", "year": "2022" }, { "DOI": "10.7326/M22-0729", "article-title": "Effect of molnupiravir on biomarkers, respiratory interventions, and medical services in COVID-19: a randomized, placebo-controlled trial", "author": "Johnson", "doi-asserted-by": "crossref", "journal-title": "Ann Intern Med", "key": "10.1016/S1473-3099(22)00507-2_bib32", "year": "2022" }, { "DOI": "10.1038/s41422-022-00619-9", "article-title": "Reduced interferon antagonism but similar drug sensitivity in omicron variant compared to delta variant of SARS-CoV-2 isolates", "author": "Bojkova", "doi-asserted-by": "crossref", "first-page": "319", "journal-title": "Cell Res", "key": "10.1016/S1473-3099(22)00507-2_bib33", "volume": "32", "year": "2022" }, { "DOI": "10.1038/s41422-022-00618-w", "article-title": "SARS-CoV-2 omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination", "author": "Li", "doi-asserted-by": "crossref", "first-page": "322", "journal-title": "Cell Res", "key": "10.1016/S1473-3099(22)00507-2_bib34", "volume": "32", "year": "2022" }, { "DOI": "10.1056/NEJMc2119407", "article-title": "Efficacy of antibodies and antiviral drugs against COVID-19 omicron variant", "author": "Takashita", "doi-asserted-by": "crossref", "first-page": "995", "journal-title": "N Engl J Med", "key": "10.1016/S1473-3099(22)00507-2_bib35", "volume": "386", "year": "2022" }, { "DOI": "10.1016/j.antiviral.2022.105252", "article-title": "Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 omicron and other variants of concern", "author": "Vangeel", "doi-asserted-by": "crossref", "journal-title": "Antiviral Res", "key": "10.1016/S1473-3099(22)00507-2_bib36", "volume": "198", "year": "2022" }, { "DOI": "10.1016/j.bmcl.2022.128629", "article-title": "Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir", "author": "Ullrich", "doi-asserted-by": "crossref", "journal-title": "Bioorg Med Chem Lett", "key": "10.1016/S1473-3099(22)00507-2_bib37", "volume": "62", "year": "2022" }, { "DOI": "10.1056/NEJMc2201933", "article-title": "Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA.2", "author": "Takashita", "doi-asserted-by": "crossref", "first-page": "1475", "journal-title": "N Engl J Med", "key": "10.1016/S1473-3099(22)00507-2_bib38", "volume": "386", "year": "2022" }, { "key": "10.1016/S1473-3099(22)00507-2_bib39", "series-title": "Hetero announces interim clinical results from phase III clinical trials of molnupiravir conducted in India", "year": "2021" }, { "DOI": "10.1126/scitranslmed.abl7430", "article-title": "A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus", "author": "Fischer", "doi-asserted-by": "crossref", "journal-title": "Sci Transl Med", "key": "10.1016/S1473-3099(22)00507-2_bib40", "volume": "14", "year": "2022" }, { "DOI": "10.3389/fphar.2022.939573", "article-title": "Antiviral efficacy and safety of molnupiravir against omicron variant infection: a randomized controlled clinical trial", "author": "Zou", "doi-asserted-by": "crossref", "journal-title": "Front Pharmacol", "key": "10.1016/S1473-3099(22)00507-2_bib42", "volume": "13", "year": "2022" }, { "article-title": "Oral antivirals for the prevention and treatment of SARS-CoV-2 infection", "author": "Soriano", "first-page": "41", "journal-title": "AIDS Rev", "key": "10.1016/S1473-3099(22)00507-2_bib43", "volume": "24", "year": "2022" }, { "DOI": "10.1016/j.dsx.2021.102329", "article-title": "Molnupiravir in COVID-19: a systematic review of literature", "author": "Singh", "doi-asserted-by": "crossref", "journal-title": "Diabetes Metab Syndr", "key": "10.1016/S1473-3099(22)00507-2_bib46", "volume": "15", "year": "2021" }, { "DOI": "10.1002/em.22471", "article-title": "Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir", "author": "Waters", "doi-asserted-by": "crossref", "first-page": "37", "journal-title": "Environ Mol Mutagen", "key": "10.1016/S1473-3099(22)00507-2_bib47", "volume": "63", "year": "2022" }, { "DOI": "10.1093/infdis/jiab247", "article-title": "β-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells", "author": "Zhou", "doi-asserted-by": "crossref", "first-page": "415", "journal-title": "J Infect Dis", "key": "10.1016/S1473-3099(22)00507-2_bib48", "volume": "224", "year": "2021" }, { "DOI": "10.3390/ijms23073507", "article-title": "Potential resistance of SARS-CoV-2 main protease (Mpro) against protease inhibitors: lessons learned from HIV-1 protease", "author": "Mótyán", "doi-asserted-by": "crossref", "journal-title": "Int J Mol Sci", "key": "10.1016/S1473-3099(22)00507-2_bib49", "volume": "23", "year": "2022" } ], "reference-count": 37, "references-count": 37, "relation": {}, "resource": { "primary": { "URL": "https://linkinghub.elsevier.com/retrieve/pii/S1473309922005072" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Infectious Diseases" ], "subtitle": [], "title": "Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy" }